
|Articles|September 10, 2015
Rob Fox
Author(s)Rob Fox
Advertisement
Rob works within the global business development team consulting with pharmaceutical and biotech companies to identify and implement strategic solutions to meet their global access needs.
With more than 13 years experience in managed access programmes; he has worked across a range of therapeutic areas including oncology, critical care, HIV and orphan diseases. In co-ordination with our regulatory, medical and operations teams, he has initiated and delivered more than 50 access programmes on behalf of our partners and is an expert in the complexities of global access throughout a product’s lifecycle.
He earned a BA honours degree in business economics from the University of Liverpool.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
5




